There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Santi Bullich |
| Institution: | Life Molecular Imaging GmbH |
| Department: | Clinical R&D |
| Country: | |
| Proposed Analysis: | In vivo characterization of the pathological deposition of tau protein in the human brain by PET imaging is a promising tool for clinical practice and in drug development trials of Alzheimer's disease. Several tau PET radiotracers have been proposed (e.g., Flortaucipir (tauvid), MK-6340, PI-2620), and one of these tracers has already been approved by FDA. Life Molecular Imaging has developed a visual assessment algorithm for 18F-PI-2620 PET scans to characterize global and regional abnormal tau deposition. This reading rubric was evaluated in a sample of 100 18F-PI-2620 PET scans that were read by eight trained physicians providing a high reproducibility. The present investigation aims to further validate the visual assessment method in an extended sample, including scans from the ADNI4 study, by assessing the reproducibility of the reading algorithm, correlation with the clinical diagnosis, and correlation with the quantitative assessment. Additionally, the potential benefits of using quantitative information obtained from PET scans as an adjunct to visual inspection will also be assessed. |
| Additional Investigators |
